Similar articles for PMID: 23236362

1

Cite

Share

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.

Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ. Cuthbertson DJ, et al. PLoS One. 2012;7(12):e50117. doi: 10.1371/journal.pone.0050117. Epub 2012 Dec 6. PLoS One. 2012. PMID: 23236362 Free PMC article.

Cite

Share

2

Cite

Share

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group. Buse JB, et al. Lancet. 2009 Jul 4;374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0. Epub 2009 Jun 8. Lancet. 2009. PMID: 19515413 Clinical Trial.

Cite

Share

3

Cite

Share

Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.

Guo W, Tian W, Lin L, Xu X. Guo W, et al. Diabetes Res Clin Pract. 2020 Dec;170:108487. doi: 10.1016/j.diabres.2020.108487. Epub 2020 Oct 6. Diabetes Res Clin Pract. 2020. PMID: 33035599 Clinical Trial.

Cite

Share

4

Cite

Share

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Sathyanarayana P, et al. Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9. Obesity (Silver Spring). 2011. PMID: 21660077 Free article. Clinical Trial.

Cite

Share

5

Cite

Share

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.

Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, Jacquier A, Lefur Y, Bernard M, Gaborit B. Dutour A, et al. Diabetes Obes Metab. 2016 Sep;18(9):882-91. doi: 10.1111/dom.12680. Epub 2016 May 31. Diabetes Obes Metab. 2016. PMID: 27106272 Clinical Trial.

Cite

Share

6

Cite

Share

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.

de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K. de Boer SA, et al. Int J Clin Pharm. 2016 Feb;38(1):144-51. doi: 10.1007/s11096-015-0219-8. Epub 2015 Nov 23. Int J Clin Pharm. 2016. PMID: 26597956 Free PMC article.

Cite

Share

7

Cite

Share

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Vilsbøll T, et al. BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771. BMJ. 2012. PMID: 22236411 Free PMC article. Review.

Cite

Share

8

Cite

Share

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.

Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan H, Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J. Yan J, et al. Hepatology. 2019 Jun;69(6):2414-2426. doi: 10.1002/hep.30320. Epub 2019 Feb 22. Hepatology. 2019. PMID: 30341767 Free PMC article. Clinical Trial.

Cite

Share

9

Cite

Share

[Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].

Camafort-Babkowski M. Camafort-Babkowski M. Med Clin (Barc). 2013 Aug 17;141(4):167-74. doi: 10.1016/j.medcli.2012.11.016. Epub 2013 Jan 18. Med Clin (Barc). 2013. PMID: 23332622 Review. Spanish.

Cite

Share

10

Cite

Share

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

Pinelli NR, Hurren KM. Pinelli NR, et al. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.

Cite

Share